Health Care • Medical/Dental Instruments
$83.56 ▲ +1.71
(+2.09%)
MKT CAP: $14.22B • VOL: 1.09M
52W L $62 52W H $94
SOLV // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $8.32B | $8.25B | $8.20B |
| YoY Revenue Growth % | +0.9% | +0.7% | — |
| Gross Profit | $4.45B | $4.59B | $3.61B |
| Gross Margin % | 53.5% | 55.6% | 44.0% |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | $2.18B | $1.04B | $1.69B |
| Operating Margin % | 26.2% | 12.6% | 20.6% |
| Net Income (GAAP) | $1.56B | $479.0M | $1.35B |
| EBITDA (Normalized) | $2.48B | $1.34B | $1.99B |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | $369.0M | $1.19B | $1.92B |
| Capital Expenditures (CapEx) | $379.0M | $380.0M | $368.9M |
| Free Cash Flow (FCF) | -$10.0M | $805.0M | $1.55B |
| FCF Margin % | -0.1% | 9.8% | 18.9% |
| Return on Invested Capital (ROIC %) | 18.7% | 8.2% | 22.5% |
| Cash & Short-Term Equivalents | $878.0M | $762.0M | $1.08B |
| Total Debt (Short + Long Term) | $5.04B | $7.81B | $2.30B |
| Total Stockholders' Equity | $5.05B | $2.96B | $4.72B |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR SOLV.